




英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation, the Chinese original shall prevail.



2026

第一季度报告

The First Quarter Report

目 录

Contents

重要内容提示 Important Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	9
三、季度财务报表 III Quarterly Financial Statements	13

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真实、准确、完整。

第一季度财务报表是否经审计

否

Important Notes

The Board of Directors and directors, and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.

The legal representative, chief accountant, and head of accounting department (accounting supervisor) hereby certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the first quarter financial statements are audited

No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目 Item	本报告期 Current reporting period	上年同期 Same period of the previous year	本报告期比上年同期增减变 动幅度(%) Increase/decrease during the reporting period over the same period of the previous year (%)
营业收入 Operating income	878,108,964.52	984,867,402.61	-10.84
利润总额 Total profit	212,643,078.03	360,390,884.31	-41.00
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	192,485,871.22	311,918,723.02	-38.29
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	186,069,686.50	214,645,947.22	-13.31
经营活动产生的现金流量净额 Net cash flows from operating activities	171,674,399.62	158,746,266.77	8.14
基本每股收益(元/股) Basic earnings per share (RMB per share)	0.33	0.53	-37.74
稀释每股收益(元/股) Diluted earnings per share (RMB per share)	0.33	0.53	-37.74
加权平均净资产收益率(%) Weighted average return on net assets (%)	1.64	2.78	增加1.14个百分点 Increase by 1.14 percentage points
	本报告期末 End of the current reporting period	上年度末 End of the previous year	本报告期末比上年度末增减 变动幅度(%) Change in the current reporting period over the end of the previous year (%)
总资产 Total assets	12,679,782,843.92	12,627,043,306.54	0.42
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company	11,826,155,581.03	11,628,469,164.23	1.70

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring gains and losses

单位: 元 币种: 人民币
Unit: RMB

非经常性损益项目	Items of non-recurring gains and losses	本期金额 Amount for the current reporting period	说明 Note
非流动性资产处置损益, 包括已计提资产减值准备的冲销部分	Gains and losses on disposal of non-current assets, including the reversal of previously recognized asset impairment provisions	-46,815.35	
计入当期损益的政府补助, 但与公司正常经营业务密切相关、符合国家政策规定、按照确定的标准享有、对公司损益产生持续影响的政府补助除外	Government grants recognized in profit or loss for the current period, excluding those closely related to the Company's business, in compliance with national policy regulations, received according to established criteria, and having a continuous impact on the Company's profit or loss	1,109,382.53	
除同公司正常经营业务相关的有效套期保值业务外, 非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益	Gains and losses from changes in the fair value of financial assets and liabilities held by non-financial corporations, and gains and losses from the disposal of financial assets and liabilities, except for effective hedging operations related to the Company's normal business operations	7,578,920.93	
除上述各项之外的其他营业外收入和支出	Non-operating income and expenses other than those listed above	-1,076,715.33	
其他符合非经常性损益定义的损益项目	Other items of profit or loss that meet the definition of non-recurring gains and losses		
减: 所得税影响额	Less: Amount affected by income tax	1,148,588.06	
少数股东权益影响额(税后)	Effect of minority interests (after tax)		
合计	Total	6,416,184.72	

对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非经常性损益项目且金额重大的, 以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目, 应说明原因。

For items of non-recurring gains and losses that the Company has recognized as items of non-recurring gains and losses not listed in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No.1 - Non-recurring Gains and Losses" and the amount of which is material, as well as items defined as non-recurring gains and losses in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No.1 - Non-recurring Gains and Losses", the reasons shall be explained.

单位：元 币种：人民币
Unit: RMB

项目名称 Item	涉及金额 Amount	原因 Reason
递延收益的摊销 Amortization of deferred income	3,470,234.70	本公司将资产相关的政府补助递延收益的摊销认定为经常性损益。 The Company recognizes the amortization of deferred income from asset-related government grants as recurring gains and losses.

(三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes in major accounting data and financial indicators, and the reasons therefor

项目名称 Item	变动比例(%) Percentage of change (%)	主要原因 Main Reason
利润总额 Total profit	-41.00	见表格下方说明。 See note below the table.
归属于上市公司股东的净利润 Net profit attributable to shareholders of listed companies	-38.29	见表格下方说明。 See note below the table.
基本每股收益 Basic earnings per share	-37.74	主要系本报告期归属于上市公司股东的净利润同比增加。 Mainly due to the increase in net profit attributable to shareholders of the listed company.
稀释每股收益 Diluted earnings per share	-37.74	主要系本报告期归属于上市公司股东的净利润同比增加。 Mainly due to the increase in net profit attributable to shareholders of the listed company.

利润总额变动原因：

2026年第一季度，公司利润总额为2.13亿元，同比减少1.48亿元。利润总额同比减少原因：一是非经常性损益(税前)较上年同期减少1.07亿元，上年同期有收到诉讼执行款0.61亿元，本期无此事项；权益工具及理财公允价值变动收益较上年同期减少0.43亿元。二是经常性损益(税前)较上年同期减少0.41亿元，主要因营业收入较上年同期下降1.07亿元，其中国内销售收入同比下降2.05亿元，国际销售收入同比增加0.52亿元，国际特许权服务收入及其他同比增加0.46亿元。2026年一季度，公司制剂销量为2,574.25万支，同比增长7.48%。

Reasons for Changes in Total Profit:

In the first quarter of 2026, the Company's total profit was RMB 213 million, a year-on-year decrease of RMB 148 million. The reasons for the decrease in total profit are as follows: First, non-recurring gains and losses (pre-tax) decreased by RMB 107 million compared with the same period last year. In the same period last year, the Company received RMB 61 million from litigation proceeds, whereas no such event occurred in the current period. In addition, fair value changes in equity instruments and wealth management products decreased by RMB 43 million year-on-year. Second, recurring gains and losses (pre-tax) decreased by RMB 41 million year-on-year, primarily due to a decrease of RMB 107 million in operating revenue compared with the same period last year. Within this, domestic sales revenue decreased by RMB 205 million year-on-year, while international sales revenue increased by RMB 52 million year-on-year, and international royalty service revenue and others increased by RMB 46 million year-on-year. In the first quarter of 2026, the Company's sales volume of pharmaceutical preparations reached 26 million

营业收入下降主要受以下因素影响：
税制口径变化(公司自2026年1月1日起由增值税简易征收(3%征收率)变更为一般计税方法(13%税率))、国际销售收入占比提高及国内外产品生产切换对实际产能的短期影响所致。

归属于上市公司股东的净利润：
2026年第一季度，公司归属于上市公司股东的净利润为1.92亿元，同比减少1.19亿元。主要是非经常性损益(税后)较上年同期减少0.91亿元所致。

units, a year-on-year increase of 7.48%.

The decline in operating revenue was mainly attributable to changes in tax calculation methods (the Company switched from the simplified VAT method (3% tax rate) to the general VAT method (13% tax rate) effective January 1, 2026), the increased proportion of international sales revenue, and the short-term impact of production switching between domestic and international products on actual production capacity.

Net Profit Attributable to Shareholders of the Listed Company:
In the first quarter of 2026, the Company's net profit attributable to shareholders of the listed company was RMB 192 million, a year-on-year decrease of RMB 119 million. This was primarily due to a decrease of RMB 91 million in non-recurring gains and losses (post-tax) compared with the same period last year.

股东信息

Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数

(I) Total number of ordinary shareholders, the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholding

单位：股
Unit: Share

报告期末普通股股东总数	81,965	报告期末表决权恢复的优先股股东总数(如有)	0		
Total number of ordinary shareholders at the end of the current reporting period	81,965	Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any)	0		
前10名股东持股情况(不含通过转融通出借股份)					
Shareholdings of top ten shareholders (excluding lending of shares through a swap)					
股东名称	Shareholder name	持股数量	持股比例(%)	持有有限售条件股份数量	质押、标记或冻结情况
		Number of shares held	Shareholding ratio (%)	Number of restricted shares held	Status of shares pledged, tagged, or frozen
股份状态	Share status	数量		数量	数量
					Number
甘忠如	Zhongru Gan	205,643,757	34.43	28,508,550	无 None
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co., Ltd.	32,073,734	5.37		质押 Pledged
全国社保基金一一三组合	The No. 113 Fund of the National Social Security Fund	11,728,290	1.96		无 None
基本养老保险基金八零二组合	Basic Pension Fund 802 Portfolio	10,840,329	1.81		无 None
甘喜茹	Xiru Gan	6,008,976	1.01		质押 Pledged
上海银行股份有限公司—银华中证创新药产业交易型开放式指数证券投资基金	Shanghai Bank Co., Ltd. - Yin Hua CSI Innovation Medicine Industry Exchange-Traded Open-End Index Securities Investment Fund	5,546,194	0.93		无 None
中国银行股份有限公司—招商中证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	5,240,400	0.88		无 None

单位：股
Unit: Share

股东名称	前10名股东持股情况(不含通过转融通出借股份)						
	Shareholder name	Shareholdings of top ten shareholders (excluding lending of shares through a swap)	Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件 股份数量 Number of restricted shares held	质押、标记或冻结情况 Status of shares pledged, tagged, or frozen
			股东性质 Nature of shareholders				股份状态 Share status
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited		其他 Other	4,889,873	0.82		无 None
HH G&L Holdings (HK) Limited	HH G&L Holdings (HK) Limited		境外法人 Overseas legal entity	4,296,032	0.72	4,296,032	无 None
招商银行股份有限公司-南方阿尔法混合型证券投资基金	China Merchants Bank Co., Ltd. - Southern Alpha Hybrid Securities Investment Fund		其他 Other	3,428,599	0.57		无 None

前10名无限售条件股东持股情况(不含通过转融通出借股份)				单位: 股
Shareholdings of top ten shareholders (excluding lending of shares through a swap)				Unit: Share
股东名称	Shareholder name	持有无限售条件流通股的数量	股份种类	股份种类及数量
		Number of unlimited shares outstanding	Category	Category and number of shares
				数量
				Number
甘忠如	Zhongru Gan	177,135,207	人民币普通股	177,135,207
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co., Ltd.	32,073,734	人民币普通股	32,073,734
全国社保基金一一三组合	The No. 113 Fund of the National Social Security Fund	11,728,290	人民币普通股	11,728,290
基本养老保险基金八零二组合	Basic Pension Fund 802 Portfolio	10,840,329	人民币普通股	10,840,329
甘喜茹	Xiru Gan	6,008,976	人民币普通股	6,008,976
上海银行股份有限公司—银华中证创新药产业交易型开放式指数证券投资基金	Shanghai Bank Co., Ltd. - Yin Hua CSI Innovation Medicine Industry Exchange-Traded Open-End Index Securities Investment Fund	5,546,194	人民币普通股	5,546,194
中国银行股份有限公司—招商国证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	5,240,400	人民币普通股	5,240,400
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited	4,889,873	人民币普通股	4,889,873
招商银行股份有限公司—南方阿尔法混合型证券投资基金	China Merchants Bank Co., Ltd. - Southern Alpha Hybrid Securities Investment Fund	3,428,599	人民币普通股	3,428,599
中国银行股份有限公司—广发中证创新药产业交易型开放式指数证券投资基金	BOC (Bank of China) - GF CSI Innovative Pharmaceutical Industry ETF	3,188,375	人民币普通股	3,188,375
上述股东关联关系或一致行动的说明	Explanation of the above shareholders' affiliation or concerted action			公司控股股东、实际控制人甘忠如持有旭特宏达96.28%的股权;甘喜茹为甘忠如胞妹。除以上情况外,其他股东之间不存在关联关系或一致行动。 Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 96.28% of the shares of Beijing Xute Hongda Technology Co., Ltd. Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders.
前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有)	Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and lending of shares in the transfer and refinancing business (if any)			不适用 N/A

季度财务报表

Quarterly Financial Statements



三、季度财务报表

III Quarterly Financial Statements

(一) 财务报表

(I) Financial statements

合并资产负债表
Consolidated statement of financial position

2026年3月31日
March 31, 2026

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2026年3月31日 March 31, 2026	2025年12月31日 December 31, 2025
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	2,165,031,863.77	2,088,313,116.28
交易性金融资产	Financial assets held for trading	1,251,076,438.36	1,401,114,684.93
应收票据	Notes receivable	6,544,573.08	6,078,174.99
应收账款	Accounts receivable	407,660,590.73	593,231,015.05
应收款项融资	Financing receivables	33,644,381.33	561,084.73
预付款项	Prepayments	87,495,016.76	55,480,540.46
其他应收款	Other receivables	5,816,585.02	3,759,148.34
存货	Inventories	1,090,338,439.90	1,008,687,851.59
一年内到期的非流动资产	Non-current assets due within one year	326,893,750.00	324,456,250.00
其他流动资产	Other current assets	28,050,973.55	2,387,272.78
流动资产合计	Total current assets	5,402,552,612.50	5,484,069,139.15
非流动资产:	Non-current Assets:		
债权投资	Debt investment	188,667,065.26	187,438,589.23
长期股权投资	Long-term equity investment	264,150,000.00	264,150,000.00
其他非流动金融资产	Other non-current financial assets	26,490,952.42	68,937,018.25
固定资产	Fixed assets	3,153,753,128.21	3,180,567,912.45
在建工程	Construction in progress	357,512,975.46	393,466,750.17
使用权资产	Right-of-use assets	3,011,953.45	3,412,247.56
无形资产	Intangible assets	509,388,594.92	265,113,204.04
开发支出	Development expenditures	1,579,221,990.32	1,611,487,766.42
长期待摊费用	Long-term deferred expenses		10,504.33
递延所得税资产	Deferred tax assets	220,364,789.87	213,669,657.49
其他非流动资产	Other non-current assets	974,668,781.51	954,720,517.45
非流动资产合计	Total non-current assets	7,277,230,231.42	7,142,974,167.39
资产总计	Total assets	12,679,782,843.92	12,627,043,306.54
流动负债:	Current Liabilities		
应付账款	Accounts payable	147,713,479.34	134,407,798.36
合同负债	Contract liabilities	54,959,007.18	67,880,818.01

合并资产负债表 (续)
Consolidated statement of financial position (Continued)

项目	Item	2026年3月31日 March 31, 2026	2025年12月31日 December 31, 2025
应付职工薪酬	Payroll and employee benefits payable	156,968,288.54	187,264,485.58
应交税费	Taxes payable	34,396,768.39	50,873,900.40
其他应付款	Other payables	272,754,769.43	360,327,524.24
一年内到期的非流动负债	Non-current liabilities due within one year	8,270,942.07	8,990,459.93
其他流动负债	Other current liabilities	1,462,631.73	6,041,815.11
流动负债合计	Total current liabilities	676,525,886.68	815,786,801.63
非流动负债：	Non-current Liabilities:		
租赁负债	Lease liabilities	2,267,912.76	2,539,557.29
长期应付款	Long-term payable	2,955,452.76	9,501,468.09
递延收益	Deferred income	169,901,840.19	170,746,315.30
非流动负债合计	Total non-current liabilities	175,125,205.71	182,787,340.68
负债合计	Total liabilities	851,651,092.39	998,574,142.31
所有者权益(或股东权益)：	Owners' (or Shareholders') equity:		
实收资本(或股本)	Paid-in capital (or share capital)	597,304,969.00	597,304,969.00
资本公积	Capital reserve	3,539,387,629.93	3,533,621,701.64
减：库存股	Less: Treasury share	111,168,980.00	111,168,980.00
其他综合收益	Other comprehensive income	2,497,688.53	3,063,071.24
盈余公积	Surplus reserve	300,532,645.00	300,532,645.00
未分配利润	Retained earnings	7,497,601,628.57	7,305,115,757.35
归属于母公司所有者权益(或股东权益)合计	Total owner's equity (or shareholders' equity) attributable to the parent company	11,826,155,581.03	11,628,469,164.23
少数股东权益	Non-controlling interests	1,976,170.50	
所有者权益(或股东权益)合计	Total owners' (or shareholders') equity	11,828,131,751.53	11,628,469,164.23
负债和所有者权益(或股东权益)总计	Total liabilities and owners' (or Shareholders') equity	12,679,782,843.92	12,627,043,306.54

公司负责人： 陈伟

主管会计工作负责人： 王琦

会计机构负责人： 周丽

Legal Representative: Wei Chen

Chief Accountant: Qi Wang

Head of Accounting Department: Li Zhou

合并利润表

Consolidated Income Statement

2026年1—3月
Jan. to Mar., 2026编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2026年第一季度 First quarter of 2026	2025年第一季度 First quarter of 2025
一、营业总收入	I. Total Revenue	878,108,964.52	984,867,402.61
其中:营业收入	Of which: Operating income	878,108,964.52	984,867,402.61
二、营业总成本	II. Total operating costs	682,007,364.82	739,374,819.17
其中:营业成本	Of which: Operating costs	223,401,494.05	228,909,866.25
税金及附加	Taxes and surcharges	13,626,505.32	9,066,767.40
销售费用	Selling expenses	270,478,075.88	326,526,305.76
管理费用	General and administrative expenses	56,772,723.33	69,653,246.71
研发费用	R&D expenses	128,036,994.79	130,445,929.06
财务费用	Financial expenses	-10,308,428.55	-25,227,296.01
加:其他收益	Add: Other income	5,879,914.51	5,061,170.15
投资收益(损失以“-”号填列)	Investment income or loss (loss is indicated with "-")	4,510,180.34	3,388,058.82
公允价值变动收益(损失以“-”号填列)	Gain or loss on the changes in fair value (loss is indicated with "-")	6,734,716.62	46,991,997.72
信用减值损失(损失以“-”号填列)	Credit impairment losses (loss is indicated with "-")	499,527.09	-1,891,609.87
资产减值损失(损失以“-”号填列)	Assets impairment losses (loss is indicated with "-")	40,670.45	
资产处置收益(损失以“-”号填列)	Gain or loss from disposal of assets (loss is indicated with "-")	-77.07	
三、营业利润(亏损以“-”号填列)	III. Operating Profit (loss is indicated with "-")	213,766,531.64	299,042,200.26
加:营业外收入	Add: Non-operating income	538,261.57	61,874,025.33
减:营业外支出	Less: Non-operating expenses	1,661,715.18	525,341.28
四、利润总额(亏损总额以“-”号填列)	IV. Profit before tax (loss is indicated with "-")	212,643,078.03	360,390,884.31
减:所得税费用	Less: Income tax expense	20,181,036.31	48,472,161.29
五、净利润(净亏损以“-”号填列)	V. Net Profit (loss is indicated with "-")	192,462,041.72	311,918,723.02
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“-”号填列)	1. Net profit from continuing operations (loss is indicated with "-")	192,462,041.72	311,918,723.02

合并利润表 (续)
Consolidated Income Statement (Continued)

项目	Item	2026年第一季度 First quarter of 2026	2025年第一季度 First quarter of 2025
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润(净亏损以“-”号填列)	1. Net profit attributable to owners of the parent (net loss is indicated with "-")	192,485,871.22	311,918,723.02
2. 少数股东损益(净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (net loss is indicated with "-")	-23,829.50	
六、其他综合收益的税后净额	VI. Other comprehensive income net of tax	-565,382.71	338,986.22
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent company	-565,382.71	338,986.22
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income cannot be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-565,382.71	338,986.22
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-565,382.71	338,986.22
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income net of tax attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	191,896,659.01	312,257,709.24
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	191,920,488.51	312,257,709.24
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-23,829.50	
八、每股收益：	VIII. Earnings Per Share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (RMB per share)	0.33	0.53
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (RMB per share)	0.33	0.53

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was RMB 0, and that generated during the previous period was RMB 0.

公司负责人：陈伟

主管会计工作负责人：王琦

会计机构负责人：周丽

Legal Representative: Wei Chen

Chief Accountant: Qi Wang

Head of Accounting Department: Li Zhou

合并现金流量表

Consolidated Statement of Cash Flows

2026年1—3月
Jan. to Mar., 2026编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2026年第一季度 First quarter of 2026	2025年第一季度 First quarter of 2025
一、经营活动产生的现金流量: I. Cash Flows from Operating Activities:			
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	1,090,250,158.47	908,976,184.90
收到的税费返还	Tax refunds received	2,386,431.91	40,666,316.18
收到其他与经营活动有关的现金	Cash received relating to other operating activities	7,832,632.42	67,079,616.13
经营活动现金流入小计	Sub-total of cash inflows from operating activities	1,100,469,222.80	1,016,722,117.21
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	232,102,273.63	261,817,120.26
支付给职工及为职工支付的现金	Cash paid to and on behalf of employees	249,657,172.46	244,825,723.94
支付的各项税费	Cash paid for taxes	153,438,987.04	103,046,569.52
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	293,596,390.05	248,286,436.72
经营活动现金流出小计	Sub-total of cash outflows from operating activities	928,794,823.18	857,975,850.44
经营活动产生的现金流量净额	Net cash flows from operating activities	171,674,399.62	158,746,266.77
二、投资活动产生的现金流量: II. Cash Flows from Investing Activities:			
收回投资收到的现金	Cash received from recovery of investments	2,141,017,904.81	2,022,569,770.00
取得投资收益收到的现金	Cash receipts from investment income	31,481,665.15	34,674,396.05
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets		819,494.19
收到其他与投资活动有关的现金	Other cash received related to investing activities	2,936,859.65	
投资活动现金流入小计	Sub-total of cash inflows from investing activities	2,175,436,429.61	2,058,063,660.24
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets, and other non-current assets	309,117,926.09	157,871,020.42
投资支付的现金	Cash paid for investments	2,120,968,400.00	1,872,948,242.74

合并现金流量表 (续)
Consolidated Statement of Cash Flows (Continued)

项目	Item	2026年第一季度 First quarter of 2026	2025年第一季度 First quarter of 2025
支付其他与投资活动有关的现金	Cash paid relating to other investing activities		
投资活动现金流出小计	Sub-total of cash outflows from investing activities	2,430,086,326.09	2,030,819,263.16
投资活动产生的现金流量净额	Net cash flows from investing activities	-254,649,896.48	27,244,397.08
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
吸收投资收到的现金	Cash received from capital contributions	2,000,000.00	
筹资活动现金流入小计	Subtotal of cash inflows from financing activities	2,000,000.00	
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	241,788.60	75,214,479.70
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	241,788.60	75,214,479.70
筹资活动产生的现金流量净额	Net cash flow from financing activities	1,758,211.40	-75,214,479.70
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	-2,074,601.28	1,466,877.94
五、现金及现金等价物净增加额	V. Net increase in cash and cash equivalents	-83,291,886.74	112,243,062.09
加：期初现金及现金等价物余额	Add: Cash and cash equivalents at beginning of period	343,530,556.97	260,055,136.76
六、期末现金及现金等价物余额	VI. Cash and cash equivalents at end of period	260,238,670.23	372,298,198.85

公司负责人：陈伟

主管会计工作负责人：王琦

会计机构负责人：周丽

Legal Representative: Wei Chen

Chief Accountant: Qi Wang

Head of Accounting Department:

Li Zhou

特此公告

Hereby announced officially.

甘李药业股份有限公司董事会
The Board of Directors of Gan & Lee Pharmaceuticals.

2026年4月21日
April 21, 2026



SCIENCE EXCELLENCE

甘李药业有限公司

Gan & Lee Pharmaceuticals.

地址：北京市通州区潮县镇南凤西一路8号

Address: No. 8, Nanfeng West 1st Street, Huoxian, Tongzhou District, Beijing

网址：<http://www.ganlee.com>

Website: <https://www.ganlee.com.cn>

电话：+86 010-80593699

Tel: +86 010-80593699

邮编：101109

Post code : 101109